**Applications**
ACE-031 was developed to treat chronic muscle-wasting diseases, including Duchenne muscular dystrophy and other forms of muscular dystrophy. Preclinical and clinical studies have also explored its effects on muscle mass, bone density, and body composition; for instance, increases in lean body mass and thigh muscle volume were observed in postmenopausal women.
In the realms of bodybuilding and sports, ACE-031 is classified as a prohibited substance (Category S4: Hormone and Metabolic Modulators) by the World Anti-Doping Agency (WADA) due to its significant potential to promote muscle growth. Although it was never approved for commercial use, it circulates on the black market under the guise of a "research chemical"; however, third-party testing has revealed that many black-market products contain inaccurate ingredients or lack the necessary Fc-fusion structure.
**Mechanism of Action**
ACE-031 functions as a "ligand trap." Its ActRIIB extracellular domain binds with high affinity to myostatin (GDF-8), activin A, and other TGF-β family ligands that signal through the ActRIIB receptor. Under physiological conditions, these ligands bind to cell-surface ActRIIB receptors, activating downstream signaling pathways that inhibit muscle protein synthesis and promote muscle breakdown. ACE-031 intercepts these ligands in a soluble form, preventing them from binding to endogenous receptors and thereby relieving the inhibition of muscle growth.
Unlike monoclonal antibodies that target only myostatin, ACE-031 blocks multiple negative regulatory ligands, demonstrating a comprehensive promoting effect on both Type I and Type II muscle fibers in animal models. In mouse experiments, ACE-031 increased gastrocnemius wet weight by 46% and increased the cross-sectional area of soleus and plantaris muscle fibers by 22% and 57%, respectively-effects that occurred independently of muscle fiber type.
Potential Benefits in Bodybuilding
Based on preclinical and early clinical data, the theoretical benefits of ACE-031 in a bodybuilding context include:
Significant increases in lean body mass. In a single ascending-dose study involving healthy volunteers, ACE-031 demonstrated a dose-related trend toward muscle growth; among postmenopausal women, a single dose resulted in a 3.3% increase in lean body mass and a 5.1% increase in thigh muscle volume.
Comprehensive muscle fiber activation. Unlike myostatin inhibitors that selectively target Type II fibers, ACE-031 promotes increases in the cross-sectional area of both Type I and Type II muscle fibers, implying potential benefits for fibers associated with both endurance and explosive power.
Trends toward optimized body composition. Trends of increased lean body mass, decreased fat mass, and increased bone density were observed in DMD clinical trials, although these did not reach statistical significance.
It is important to note that ACE-031 was never approved for human use; safety concerns-specifically vascular-related events-led to the termination of its clinical development. Any use of the drug is considered experimental or non-compliant.
Clinical and Research Cases
Phase I trial in healthy volunteers (2010–2013). A single ascending-dose study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics. Results indicated that ACE-031 was generally well-tolerated and demonstrated dose-related increases in lean body mass.
Study in postmenopausal women. Following a single dose of ACE-031, DEXA scans showed a 3.3% increase in lean body mass and MRI showed a 5.1% increase in thigh muscle volume, confirming the muscle-building effects of ActRIIB ligand blockade in humans.
Phase II clinical trial for DMD (2010–2012). A randomized, placebo-controlled trial involving ambulatory boys with DMD showed that the ACE-031 group exhibited a trend toward maintaining 6-minute walk distance (whereas the placebo group showed a decline), along with trends toward increased lean body mass and bone density. However, the trial was terminated early after the second dosing regimen due to safety signals such as epistaxis and telangiectasia.
Long-term non-human primate study (published in 2026): A 14-week dosing study in common marmosets demonstrated that ACE-031 (3 mg/kg, once weekly) significantly increased lean body mass, increased the cross-sectional area of both Type I and Type II muscle fibers in the biceps, and enhanced *ex vivo* muscle contractile force. This study provides further support for the potential value of ActRIIB-targeted strategies in treating human myopathies.
Why Choose Us
In the field of research-grade ACE-031, supply chain standardization and product quality are directly linked to experimental reproducibility and the reliability of downstream data. As the primary manufacturer, we offer the following core advantages:
Professional production equipment and process control: We utilize a mammalian cell expression system to produce the ACE-031 fusion protein, ensuring correct glycosylation and protein folding. Our production line is equipped with standardized bioreactors and downstream purification systems, with strict process controls implemented for every batch.
Stable supply: Our direct-from-factory model eliminates intermediaries, ensuring supply continuity between batches and mitigating the risk of stockouts caused by distribution channel fluctuations.
High purity and consistent quality: Products undergo Protein A/G affinity purification, with purity verified at ≥95% via SDS-PAGE. A Certificate of Analysis (COA) is provided for every batch, covering key metrics such as purity, concentration, and endotoxin levels to ensure batch-to-batch consistency.
Guaranteed after-sales support: We provide professional assistance ranging from product inquiries to technical support. In the event of quality issues, we offer return and exchange guarantees to ensure the continuity of your research.
FAQ
Q: Where are your products manufactured?
A: Our products are manufactured in Shenzhen, China.
Q: What is the minimum order quantity (MOQ)?
A: The minimum order quantity is 10 vials/sets.
Q: What is your shipping turnaround time?
A: Orders for in-stock items are shipped within 24 hours.
Q: What purity levels do you offer? A: Standard purity is 99%.
Q: Which shipping carriers do you use?
A: Options include FedEx, DHL, UPS, and postal services.
Q: How long does shipping take?
A: Approximately 10–15 days.
Q: Can you provide COA and HPLC test reports?
A: Yes, we can; all products undergo professional testing before shipment.
Q: Do you offer OEM services?
A: Yes, OEM services are available, subject to minimum order quantity (MOQ) requirements.
Q: How do you handle after-sales issues?
A: If a quality issue attributable to our production is confirmed after the customer receives the goods, we offer free replacement or a refund. We are committed to a pragmatic and responsible service approach, actively addressing and resolving any issues without evasion or excuses, while fully safeguarding our customers' interests.
Q: What payment methods do you accept?
A: We accept bank transfers, Bitcoin, TransferWise, and Xoom.
Hot Tags: ACE-031 1mg/vial High-Purity Research Peptide – Chinese Supplier, China ACE-031 1mg/vial High-Purity Research Peptide – Chinese Supplier manufacturers, suppliers, factory
